

Innovative medicines initiative

- Under the [7th Framework Programme](#) (FP7), [Joint Technology Initiatives](#) (JTIs) have been introduced to realise Public-Private Partnerships (PPPs) in research at European level and IMI is one of these first JTIs that have been launched.
- IMI grew out of the European Technology Platform on Innovative Medicines.

- IMI's overall goal is to reinvigorate the biopharmaceutical sector in Europe.
- To reach this objective, a unique collaboration within the pharmaceutical sector will be implemented through the IMI:

For the first time, competitor pharmaceutical companies will collaborate to find solutions in order to overcome the research bottlenecks in the drug development process.

- Multiannual plan
- Based on strategic research agenda developed by the European Technology Platform on Innovative Medicines
- Focus:
 - Safety
 - Efficiency
 - Knowledge management
 - Education and training

priority	title	pillar	Scientific area
A	Assessment of drug induced toxicity in relevant organs - surrogates for early drug failure	Safety	General Safety
B	Immunological Safety of Biopharmaceuticals	Safety	Immunology
C	Assessment inflammatory disease	Efficacy	Inflammatory Diseases
D	Improve the scientific and pre-clinical infrastructure for Tuberculosis medicine	Efficacy	Infectious Diseases
E	Enhancing translation in neurological disease	Efficacy	CNS
F	Development of personalized medicine approaches in diabetes	Efficacy	Metabolic Diseases
G	Fostering a broader understanding of pharmaceutical R&D in the broader public	Education & Training	Education & Training

- Total budget (2008-2013) 2 billion €
 - Max Community contribution: 1 billion €
 - EFPIA's contribution: 1 billion €

- 1 call for proposals is published in every year
- these calls are open to all European countries.
- Consortia: at least two EFPIA member companies, + two legal entities who are not a members of EFPIA
- Project budgets shall aim at a 50:50 ratio (unless otherwise specified in the call) between in kind contributions from EFPIA Members and the financial contribution from IMI
- Peer review process

- Project funding via combined contributions from
 - EC funds
 - private
- Average project size 20 million €
- Average size of a full consortium participating in proposals after the 1st call are in the range of:
 - 9-16 pharmaceutical companies
 - 9-37 academic, SME, regulatory, patient organizations
- Budget of 1st call: 246 million €
- Budget of 2nd call: ~ 160 million €



- Call definition
- Evaluation 1st stage:
- Evaluation 2nd stage



Thank you for your attention